Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features

  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • García, Olga
  • Arnan, Montserrat
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Fuster García, Francisco|||0000-0002-2528-6143
  • Cabezón, Marta|||0000-0001-5122-7481
  • Coll, Rosa|||0000-0003-0560-1254
  • Ademà, Vera|||0000-0001-6051-4378
  • Grau Cat, Javier
  • Jiménez, Maria-José
  • Pomares, Helena
  • Marcé, Silvia|||0000-0001-9128-6822
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Millá, Fuensanta
  • Alonso, Esther
  • Sureda, Anna|||0000-0002-1238-6970
  • Gallardo, David|||0000-0003-1615-4592
  • Feliu Frasnedo, Evarist|||0000-0001-5780-3136
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Sole, F.|||0000-0002-3251-2161
  • Zamora, Lurdes|||0000-0003-1713-7110
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine

  • Cabezón, Marta|||0000-0001-5122-7481
  • Bargay, Joan|||0000-0002-6739-3916
  • Xicoy, Blanca|||0000-0002-0295-1307
  • García, Olga
  • Borrás, Josep
  • Tormo, Mar|||0000-0001-9622-1649
  • Marcé, Silvia|||0000-0001-9128-6822
  • Pedro, Carme
  • Valcárcel, David|||0000-0002-8747-078X
  • Jiménez, Maria José
  • Guàrdia, Ramón
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Brunet, Salut|||0000-0003-0491-1672
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Feliu Frasnedo, Evarist|||0000-0001-5780-3136
  • Zamora, Lurdes|||0000-0003-1713-7110
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. Overall, 95% of patients harbored at least one mutation. TP53, DNMT3A and SRSF2 were the most frequently altered genes. Mutations in TP53 correlated with higher risk features and shorter overall survival (OS) and progression free survival (PFS) in univariate analysis. Patients with SRSF2 mutations were associated with better OS and PFS. Response rate was 55%; but we could not correlate the presence of TET2 and TP53 mutations with AZA response. Patients with sAML presented more variations than patients with high-risk MDS, and usually at relapse the number of mutations increased, supporting the idea that in advanced stages of the disease there is a greater genomic complexity. These results confirm that mutation analysis can add prognostic value to high-risk MDS and sAML patients, not only at diagnosis but also at follow-up.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia

  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Ibáñez, Mariam
  • Abáigar, María
  • Vázquez, Iria
  • Álvarez, Sara
  • Cabezón, Marta|||0000-0001-5122-7481
  • Tazón-Vega, Bárbara|||0000-0003-4513-5104
  • Rapado, Inmaculada
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • Cervera, José|||0000-0001-8252-1106
  • Benito, Rocío|||0000-0001-9781-4198
  • Larrayoz, María J.
  • Cigudosa, Juan C.
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Valcárcel, David|||0000-0002-8747-078X
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Acha, Pamela|||0000-0002-4528-1219
  • Hernández-Sánchez, Jesús M.
  • Fernández-Mercado, Marta
  • Sanz, Guillermo|||0000-0002-2767-8191
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Calasanz, M.J|||0000-0002-0374-3008
  • Sole, F.|||0000-0002-3251-2161
  • Such, Esperanza|||0000-0001-6892-403X
The landscape of medical sequencing has rapidly changed with the evolution of next generation sequencing (NGS). These technologies have contributed to the molecular characterization of the myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), through the identification of recurrent gene mutations, which are present in >80% of patients. These mutations contribute to a better classification and risk stratification of the patients. Currently, clinical laboratories include NGS genomic analyses in their routine clinical practice, in an effort to personalize the diagnosis, prognosis and treatment of MDS and CMML. NGS technologies have reduced the cost of large-scale sequencing, but there are additional challenges involving the clinical validation of these technologies, as continuous advances are constantly being made. In this context, it is of major importance to standardize the generation, analysis, clinical interpretation and reporting of NGS data. To that end, the Spanish MDS Group (GESMD) has expanded the present set of guidelines, aiming to establish common quality standards for the adequate implementation of NGS and clinical interpretation of the results, hoping that this effort will ultimately contribute to the benefit of patients with myeloid malignancies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

  • Cabezón, Marta|||0000-0001-5122-7481
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Bargay, Joan|||0000-0002-6739-3916
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Marcé, Silvia|||0000-0001-9128-6822
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Tormo, Mar|||0000-0001-9622-1649
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Coll, Rosa|||0000-0003-0560-1254
  • Borrás, Josep
  • Jiménez, María José|||0000-0002-5469-5237
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Valcárcel, David|||0000-0002-8747-078X
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Font, L. L.
  • Ramila, Elena
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Zamora, Lurdes|||0000-0003-1713-7110
Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. However, response rates to HMA are low and there is an unmet need in finding prognostic and predictive biomarkers of treatment response and overall survival. We performed global methylation analysis of 75 patients with high-risk MDS and secondary AML who were included in CETLAM SMD-09 protocol, in which patients received HMA or intensive treatment according to age, comorbidities and cytogenetic. Unsupervised analysis of global methylation pattern at diagnosis did not allow patients to be differentiated according to the cytological subtype, cytogenetic groups, treatment response or patient outcome. However, after a supervised analysis we found a methylation signature defined by 200 probes, which allowed differentiating between patients responding and non-responding to azacitidine (AZA) treatment and a different methylation pattern also defined by 200 probes that allowed to differentiate patients according to their survival. On studying follow-up samples, we confirmed that AZA decreases global DNA methylation, but in our cohort the degree of methylation decrease did not correlate with the type of response. The methylation signature detected at diagnosis was not useful in treated samples to distinguish patients who were going to relapse or progress. Our findings suggest that in a subset of specific CpGs, altered DNA methylation patterns at diagnosis may be useful as a biomarker for predicting AZA response and survival.